


The Fund aims to achieve long term capital growth primarily through investment in a portfolio of equities issued by continental European companies and in derivatives, the underlying assets of which are equities issued by continental European companies.
| Name | % Net Assets |
|---|---|
| Novartis | 5.5% |
| Sanofi-Synthelabo | 4.9% |
| Total SA | 4.1% |
| Bayer | 3.3% |
| Anheuser-Busch Inbev | 3.2% |
| SAP | 2.7% |
| Novo Nordisk A/S | 2.7% |
| Unilever NV | 2.6% |
| Teleperformance SA | 2.6% |
| ING Groep N.V. | 2.4% |
| Key | % Net Assets |
|---|---|
| 5.5% | |
| 4.9% | |
| 4.1% | |
| 3.3% | |
| 82.2% |
| Date | n/a |
|---|---|
| Bid | 0.00 |
| Offer | 0.00 |
| Currency | n/a |
| Change | 0.00 |
| % | n/a |
| YTD change | 0.00 |
| YTD % | n/a |
| Fund Inception | 24/09/1986 |
|---|---|
| Fund Manager | Nigel Hankin |
| TER | 1.62 (31-Dec-2011) |
| Minimum Investment | |
|---|---|
| Initial | 1000 |
| Additional | 100 |
| Savings | 100 |
| Charges | |
|---|---|
| Initial | 4.50% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.06 |
You are here: research